ADCT 301

Drug Profile

ADCT 301

Alternative Names: HuMax-TAC antibody and PBD warhead - Genmab/ADC Therapeutics; HuMax-TAC-ADC - Genmab/ADC Therapeutics; HuMax®-TAC-ADC

Latest Information Update: 03 Jul 2017

Price : $50

At a glance

  • Originator ADC Therapeutics; Genmab
  • Developer ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Immunoconjugates; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents; Interleukin 2 receptor alpha subunit antagonists; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Jun 2017 Interim adverse events and efficacy data from a phase I trial in Hodgkin's disease and Non-Hodgkin's lymphoma(Second-line therapy or greater) released by ADC Therapeutics
  • 05 Dec 2015 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (9188505; ADC pipeline, December 2015)
  • 26 Oct 2015 ADC Therapeutics plans a phase I trial for Acute myeloid leukaemia (Second-line therapy or greater) in USA (NCT02588092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top